Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use EGRIFTA WR safely and effectively. See full prescribing information for EGRIFTA WR. EGRIFTA WR™ (tesamorelin) for injection, for subcutaneous useInitial U.S. Approval: 2010
Medication labelWhy this: Advisory · dailymed-prescription
EGRIFTA WR is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Limitations of Use: Long-term cardiovascular safety of EGRIFTA WR has not been established. Consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue. EGRIFTA WR is not indicated for weight loss management as it has a weight neutral effect. There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA WR.
- generic_name
- tesamorelin
- brand_name
- bacteriostatic water
- product_names
- tesamorelin, bacteriostatic water
- ndc
- 62064-381, 62064-381-04, 62064-371, 62064-371-01, 0409-3977
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en